A Phase 1 interventional study of Clindamycin and Benzoyl Peroxide Gel 1%5% and BenzaClin® Topical Gel in Acne Vulgaris, sponsored by Taro Pharmaceuticals USA. Completed. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2017-05-04.
Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.
Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 6th largest by enrollment, is one of 5 that started in 2015, is one of 6 in phase 1, and was the 29th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:
Centre for Human Drug Research, Netherlands · Sites in Netherlands
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 9 · Phase 4 16
First in 2005; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,000 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 117 across the 34 interventional studies. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Taro Pharmaceuticals USA, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Taro Pharmaceuticals USA is the lead sponsor of 71 studies on the registry; none are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 1 (5%) have results posted.
30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited: none open now, 1 under way, none of them phase 3. Of 29 finished, 8 (28%) have results posted.
Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one is the 9th largest by enrollment, is one of 4 that started in 2015, is one of 21 in phase 1, and was the 9th registered.
Sun Pharmaceutical Industries Limited’s Acne Vulgaris studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing clindamycin in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 30 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the therapeutic equivalence and safety of Clindamycin and Benzoyl Peroxide Gel 1%/5% and BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel
The objectives of this study are to evaluate the therapeutic equivalence and safety of Clindamycin and Benzoyl Peroxide Gel 1%/5% (Taro Pharmaceuticals Inc.) and BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, US) in the treatment of acne vulgaris and to demonstrate the superiority of the efficacy of the test and reference products over the placebo control
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clindamycin and Benzoyl Peroxide Gel 1%/5% applied twice daily (morning and evening) for 70 days (10 weeks).
Drug: Clindamycin and Benzoyl Peroxide Gel 1%5%
BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel applied twice daily (morning and evening) for 70 days (10 weeks).
Drug: BenzaClin® Topical Gel
Placebo (vehicle of the test product) applied twice daily (morning and evening) for 70 days (10 weeks).
Drug: Placebo
Drug pages: Clindamycin · Benzoyl Peroxide
Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
Also known as: Active
BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
Also known as: Active
Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
Also known as: Vehicle
Change in inflammatory lesion count
Mean percent change from baseline to week 10 (study day 70) in the inflammatory (papules and pustules) lesion counts.
Time frame: Week 10 (day 70)
Change in non-inflammatory lesion count
Mean percent change from baseline to week 10 (study day 70) in the non-inflammatory (open and closed comedones) lesion counts.
Time frame: Week 10 (day 70)
Clinical response of success
The proportion of subjects with a clinical response of success at week 10 (study day 70) defined as an Investigator's Global Assessment score at least 2 grades less than baseline assessment.
Time frame: Week 10 (day 70)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jan 2015, a primary completion of Oct 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide